Background: Haemophilia with inhibitors is a rare condition, which requires a substantial amount of economical and human resources representing one of the most challenging complications of haemophilia treatment. Quality of life and self-management abilities of patients are affected by this complication. In the Italian COHIBA Study haemophilia patients with inhibitors were asked about their treatment preferences, HRQoL and treatment satisfaction. Methods: HRQoL was evaluated with the Core Instrument of the haemophilia-specific Haem-A-QoL consisting of 25 items (allowing the comparison between children and adults), treatment satisfaction was assessed with the Hemo-Sat questionnaire (for adults and parents of haemophilic children) consisting o...
Background. In Italy, the project on the social burden and quality of life (QoL) of patients with h...
Haemophilia A (HA) patients with high responding inhibitors require therapies with bypassing agents ...
Haemophilia is a congenital bleeding disorder affecting about 1 out of 10,000 people in the general ...
Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophili...
Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophili...
Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophili...
Inhibitors represent one major complication of haemophilia treatment, as they increase the risk of b...
Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and di...
Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and di...
Introduction: The B-Natural study is a multicentre, multinational, observational study of haemophili...
Introduction: Haemophilia treatment varies significantly between individuals, countries and regions ...
Summary: Increased or maintained health and quality of life (HRQoL) are essential goals in health ca...
Background: Prerequisite for optimal haemophilia care provision all around Europe is clearness on cl...
INTRODUCTION: Haemophilia treatment varies significantly between individuals, countries and regions ...
Haemophilia A (HA) patients with high responding inhibitors require therapies with bypassing agents ...
Background. In Italy, the project on the social burden and quality of life (QoL) of patients with h...
Haemophilia A (HA) patients with high responding inhibitors require therapies with bypassing agents ...
Haemophilia is a congenital bleeding disorder affecting about 1 out of 10,000 people in the general ...
Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophili...
Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophili...
Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophili...
Inhibitors represent one major complication of haemophilia treatment, as they increase the risk of b...
Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and di...
Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and di...
Introduction: The B-Natural study is a multicentre, multinational, observational study of haemophili...
Introduction: Haemophilia treatment varies significantly between individuals, countries and regions ...
Summary: Increased or maintained health and quality of life (HRQoL) are essential goals in health ca...
Background: Prerequisite for optimal haemophilia care provision all around Europe is clearness on cl...
INTRODUCTION: Haemophilia treatment varies significantly between individuals, countries and regions ...
Haemophilia A (HA) patients with high responding inhibitors require therapies with bypassing agents ...
Background. In Italy, the project on the social burden and quality of life (QoL) of patients with h...
Haemophilia A (HA) patients with high responding inhibitors require therapies with bypassing agents ...
Haemophilia is a congenital bleeding disorder affecting about 1 out of 10,000 people in the general ...